IP Library Granted Patent US 10,888,609
Granted Patent B2
US 10,888,609 · App. 15/773,527 · Granted Jan 12, 2021

CD200 inhibitors and methods of use thereof

Inventor: Michael Olin (Minneapolis, MN)
Assignee: Regents of the University of Minnesota
A61K39/0011A61K9/0019A61K39/39A61P35/02C07K7/06C07K7/08C07K14/70503A61K31/203A61K31/404A61K31/675A61K31/7068A61K38/2013A61K2039/545A61K2039/55516A61K2039/55561A61K2039/585A61K2039/6081A61K2039/80A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,609
App. No.
15/773,527
Granted
Jan 12, 2021
Kind
B2
Abstract

The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.

Claims (13)

1. A composition comprising a CD200 inhibitor, wherein the CD200 inhibitor is a mutant of naturally-occurring CD200 peptide, wherein the CD200 inhibitor is 13 to 20 amino acids in length, and wherein the peptide comprises the amino acid sequence VTWQKKAAVSPEN (SEQ ID NO: 21).

2. The composition of claim 1 , further comprising:

(i) a cancer vaccine;

(ii) a cancer vaccine that is a tumor lysate; or

(iii) a tumor lysate that is substantially devoid of CD200.

3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier and/or diluent and/or an adjuvant.

4. The composition of claim 1 , wherein the composition further comprises a cancer therapy.

5. A kit for treating cancer, comprising:

(a) a first pharmaceutical composition comprising a composition of claim 1 ; and

(b) instructions for use.

6. A nucleic acid molecule encoding a CD200 inhibitor, wherein the CD200 inhibitor is a mutant of naturally-occurring CD200 peptide, wherein the CD200 inhibitor is 13 to 20 amino acids in length, and wherein the peptide comprises the amino acid sequence VTWQKKAAVSPEN (SEQ ID NO:21).

7. An expression cassette comprising the molecule of claim 6 .

8. A viral vector comprising the expression cassette of claim 7 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2018
From: OLIN, MICHAEL
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 046618/0418 →
Continuity (2)
Provisional Application 62250376 · Nov 3, 2015
Related Publication 20180326028A1 · Nov 15, 2018
Cited By (1)
US 12,414,983